OVTOKO

The OVTOKO cell line originates from human ovarian clear cell adenocarcinoma, having been established from metastatic tumors in patients previously subjected to five to six courses of CAP chemotherapy. These cells demonstrate morphological heterogeneity, comprising small to moderately sized cuboidal cells, columnar cells, spindle-shaped cells, and malignant tumor giant cells. They consistently exhibit coexpression of cytokeratins and vimentin, indicative of an epithelial origin in culture, specifically expressing cytokeratin polypeptides 7, 8, 18, and 19. Additionally, OVTOKO cells express epidermal growth factor (EGF) receptors but lack estrogen and progesterone receptors. Notably, intraperitoneal transplantation of OVTOKO cells results in peritoneal implantation and distant metastasis, rendering them a valuable model for investigating ovarian cancer progression and therapeutic strategies.

Why choose OVTOKO from AcceGen?

OVTOKO cells from AcceGen exhibit exceptional quality with high viability, ensuring their reliability in research applications. These cells are maintained under stringent sterile conditions, rigorously tested for the absence of bacteria, fungi, and mycoplasma contamination. They are carefully incubated in optimal growth conditions and cryopreserved by skilled operators, guaranteeing their robustness and consistency for various experimental endeavors.